Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Professor Sir Mene Pangalos, Executive Vice-President (retiring) of BioPharmaceuticals R&D at AstraZeneca, has received the prestigious BioIndustry Association (BIA) Lifetime Achievement Award at the organisation’s annual gala dinner. This award is based on nominations from the BIA Board and recognises Mene's transformative impact on AstraZeneca, the UK life sciences sector and people living with disease. Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science. Mene's passion extends beyond his leadership role. He retains a keen interest in neuroscience, drug discovery, mentoring the next generation of scientists and sharing his expertise with over 150 peer-reviewed publications.

BIA Gala Key 008.jpg
© BIA
Professor Sir Mene Pangalos, Executive Vice-President (retiring) of BioPharmaceuticals R&D at AstraZeneca

His influence extends far beyond AstraZeneca. Mene is a leading figure in UK science, holding prestigious positions on boards such as The Francis Crick Institute, Cambridge University's Judge Business School, and Absci Corp. His dedication to fostering collaboration and innovation is evident from roles on the Medical Research Council, co-chairing the Life Sciences Council's Expert Group, and sitting on the UK Life Sciences Industrial Strategy Implementation Board.

Mene's contributions to medical science have been widely recognized. He is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology, and Clare Hall – University of Cambridge. In 2019, he was knighted by Her Majesty the Queen for his exceptional service to UK science and also received the 2019 Prix Galien Medal, Greece for his scientific research.

An important part of this legacy is AstraZeneca’s new R&D Discovery Centre (DISC) in Cambridge. This state-of-the-art facility, which is the largest research facility in the UK, was spearheaded by Mene and embodies his vision for collaborative scientific innovation – and is poised to play a crucial role in the future success of AstraZeneca and of the UK life science industry.

Steve Bates OBE, BIA’s CEO said: “Throughout his career Mene has championed a broad ecosystem approach to translating bioscience for patient benefit – from his time at university in London to the top of RD at a global biopharmaceutical company. He has formed key collaborations between academia and companies, large and small, in the UK and beyond, and his bold sector leadership was ably demonstrated during the pandemic.”

Professor Sir Mene Pangalos said: “I would like to express my immense gratitude for this great honour. This award really is a recognition of the contributions of all the people and teams I have worked with throughout my career. True innovation in medicine is only possible when we work together, towards a common goal: it's only thanks to the shared commitment of our scientists, our dedicated healthcare workers, and especially our patients and their families – that we can turn science into the life-changing new medicines for those who need them most.

BIA Gala Key 005.jpg
© BIA
Professor Sir Mene Pangalos being presented witha  Lifetime Achievement Award by BIA's Chair, Dan Mahony

The BIA gala delivered a night of celebration and collaboration, culminating in the launch of its Charity partnership with RNID with a fundraising and awareness activity for the 12 million people in the UK affected by deafness, hearing loss, or tinnitus. The coveted evening was attended by the brightest minds in UK biotech, the life science sector and business: industry leaders, member companies, and Andrew Griffith, Minister of State for Science, Innovation, and Technology.

Ends

Note to editors.

For more information, contact Alina O’Keeffe, Associate Director, Marketing and Communications, BIA on [email protected].

About the BioIndustry Association (BIA)

 

More news and updates 

State of the Discovery Nation report reveals the extent of sector's perfect storm

New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.

BIA teams up with top UK engineering biology stakeholders to champion the UK at SynBioBeta 2024

BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.

Post-Brexit border paperwork and inspections postponed for life sciences sector

Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

BIA responds to Spring Budget 2024: highlights for UK life sciences

Three highlights for UK life sciences: first, the new expert advisory panel for the HMRC is a smart way to maximise the efficiency of R&D tax relief support for life science innovators; secondly, Alan Marchington’s ICG winning the LIFTs scheme shows real movement to unlock pension funds for life sciences; thirdly, AstraZeneca’s investment in next-generation manufacturing in Speke and Cambridge shows the strength of our ecosystem.

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.

Resilient UK biotech sector lands £1.8 billion investment in 2023

New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.   

BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

BIA reaches 600 member companies, announces new board and leadership restructure 

The UK’s innovative trade association for life science and biotech companies, BioIndustry Association (BIA), today announces that it has reached 600 companies in membership for the first time ever, alongside new Board and staff appointments for 2024.

BIA announces its Charity Partnership for 2024 with RNID

BIA is thrilled to announce its charity partnership of the year for 2024 with RNID, the national charity supporting the 12 million people in the UK who are deaf, have hearing loss or tinnitus. 

 

More within